US 11,655,288 B2
Antibodies to oxidized phospholipids
Joseph L. Witztum, San Diego, CA (US); Sotirios Tsimikas, San Diego, CA (US); and Xuchu Que, San Diego, CA (US)
Assigned to The Regents of the University of California, Oakland, CA (US)
Filed by The Regents of the University of California, Oakland, CA (US)
Filed on May 29, 2018, as Appl. No. 15/991,792.
Application 15/991,792 is a continuation of application No. 14/770,160, abandoned, previously published as PCT/US2014/018402, filed on Feb. 25, 2014.
Claims priority of provisional application 61/894,220, filed on Oct. 22, 2013.
Claims priority of provisional application 61/769,154, filed on Feb. 25, 2013.
Prior Publication US 2018/0265576 A1, Sep. 20, 2018
Int. Cl. C07K 16/18 (2006.01); A01K 67/027 (2006.01); A61K 39/00 (2006.01)
CPC C07K 16/18 (2013.01) [A01K 67/0275 (2013.01); A01K 67/0278 (2013.01); A01K 2217/052 (2013.01); A01K 2217/15 (2013.01); A01K 2217/206 (2013.01); A01K 2227/105 (2013.01); A01K 2267/01 (2013.01); A01K 2267/0362 (2013.01); A01K 2267/0368 (2013.01); A01K 2267/0375 (2013.01); A61K 2039/505 (2013.01); C07K 2317/24 (2013.01); C07K 2317/622 (2013.01); C07K 2317/76 (2013.01)] 18 Claims
 
1. A method of treating non-alcoholic steatohepatitis (NASH) in a subject in need thereof, the method comprising administering to the subject an antibody or a fragment thereof that specifically binds to a phosphocholine (PC) headgroup of an oxidized phospholipid, the antibody comprising: a VH comprising the complementarity determining regions (CDRs) of the VH amino acid sequence set forth in SEQ ID NO: 2; and a VL comprising the CDRs of the VL amino acid sequence set forth in SEQ ID NO: 2, wherein the VH comprises the VH amino acid sequence set forth in SEQ ID NO: 2.